DEFJ, LLC - 03 Aug 2026 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Reporting relationship: 10%+ Owner
Issuer ticker: RNAZ
Reported as of: 03 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Aug 2026, 16:05:41 UTC
Prior SEC filing: 05 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Yu Ying Choi Alan Abel, Director of CK Life Sciences Int'l., (Holdings) Inc.

Key filing fact

DEFJ, LLC filed Form 4 for Transcode Therapeutics, Inc. (RNAZ) on 05 Aug 2026.

Key facts

This page summarizes DEFJ, LLC's Form 4 filing for Transcode Therapeutics, Inc. (RNAZ).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 05 Aug 2026, 16:05.

Change

Previous filing in this sequence was filed on 05 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0002147448 Primary reporting owner

DEFJ, LLC

Relationship: 10%+ Owner
Address: 7TH FL, CHEUNG KONG CENTER,, 2 QUEEN'S RD, CENTRAL HONG KONG, HONG KONG
Signature: /s/ Yu Ying Choi Alan Abel, Director of CK Life Sciences Int'l., (Holdings) Inc.
Signature date: 05 Aug 2026

CIK 0001297567

CK Life Sciences Intl (Holdings) Inc

Relationship: 10%+ Owner
Address: 7TH FL, CHEUNG KONG CENTER,, 2 QUEEN'S RD, CENTRAL HONG KONG, HONG KONG
Signature: /s/ Yu Ying Choi Alan Abel, Manager of DEFJ, LLC
Signature date: 05 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RNAZ transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +11,813,859
Change %: +3937%
Price
Shares after: 12,113,899
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

RNAZ transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +11,813,859
Change %: +3937%
Price
Shares after: 12,113,899
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

RNAZ transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,020,582
Change %: +17%
Price
Shares after: 14,134,481
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

RNAZ transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,020,582
Change %: +17%
Price
Shares after: 14,134,481
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNAZ transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -1,181
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,813,859
Exercise price
Footnotes: F1, F2, F3, F4

RNAZ transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -1,181
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,813,859
Exercise price
Footnotes: F1, F2, F3, F4

RNAZ transaction Derivative

Series B Non-Voting Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -202
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,020,582
Exercise price
Footnotes: F1, F2, F3

RNAZ transaction Derivative

Series B Non-Voting Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -202
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,020,582
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series A Non-Voting Convertible Preferred Stock") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series B Non-Voting Convertible Preferred Stock"), are convertible at any time into shares of Common Stock, par value $0.0001 per share ("Common Stock"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date.

Footnote F2

On August 3, 2026, DEFJ, LLC ("DEFJ") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock ("Certificate of Designation")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock.

Footnote F3

DEFJ, a Delaware limited liability company, is a direct, wholly owned subsidiary of Conjoint Inc., a Delaware corporation, which is a direct, wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an admission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F4

Includes 28.4291 shares of Series A Non-Voting Convertible Preferred Stock previously issued to DEFJ as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 under the Securities Exchange Act of 1934, as amended.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .